Actively Recruiting
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Led by Keymed Biosciences Co.Ltd · Updated on 2025-08-17
200
Participants Needed
1
Research Sites
72 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
CONDITIONS
Official Title
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Atopic Dermatitis for at least 1 year according to American Academy of Dermatology criteria
- Eczema Area and Severity Index (EASI) score of 16 or higher at Screening and Baseline
- Investigator's Global Assessment (IGA) score of 3 or higher at Screening and Baseline
- At least 10% Body Surface Area (BSA) affected by Atopic Dermatitis at Screening and Baseline
- Average weekly Pruritus Numeric Rating Scale (NRS) severity score of 4 or higher at Baseline
You will not qualify if you...
- Insufficient washout period from previous therapy
- Presence of concurrent diseases or conditions that could affect safety or efficacy evaluation
- Organ dysfunction
- Pregnancy
- Other unspecified exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's hospital
Beijing, China
Actively Recruiting
Research Team
Q
Qian Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here